The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
49
Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Chonbuk National University Hospital
Jeonju, South Korea
AUCt
Area under the curve of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
Time frame: 72 hr after baseline
Cmax
Peak concentration of telmisartan, amlodipine, rosuvastatin at 72 hours after baseline
Time frame: 72 hr after baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.